HBM Healthcare Investments AG has signed an agreement to sell a majority stake in Swixx BioPharma AG to SK Capital Partners, LP for 1.5 billion euros. The company will retain a significant minority interest and continue to hold a 25.1% stake in Swixx Healthcare. The transaction will result in an increase in net asset value of approximately CHF 13.50 per share. Cash proceeds from the sale are expected to exceed the reported book value as of September 30. The total investment in Swixx Biopharma amounts to 26 million euros, with added value of around CHF 300 million to date. HBM Healthcare Investments closed trading 2.11% higher at CHF 217.50 on the Swiss Stock Exchange.

Read more at NASDAQ.: HBM Healthcare To Sell Majority Stake In Swixx Biopharma To SK Capital Partners